Mitochondrion-Targeted NIR Therapeutic Agent Suppresses Melanoma by Inducing Apoptosis and Cell Cycle Arrest via...

Area of Science:

• Biomedical Engineering
• Cancer Research
• Pharmacology

Background:

• Malignant melanoma is a deadly skin cancer requiring improved diagnostic and therapeutic strategies.
• Near-infrared fluorescent heptamethine cyanine dyes offer potential for tumor diagnosis and treatment.
• Developing effective theranostic agents is crucial for enhancing cancer patient outcomes.

Purpose of the Study:

• To synthesize and evaluate a novel multifunctional theranostic agent, IR-817, for malignant melanoma.
• To investigate the anti-cancer effects and mechanisms of IR-817 in vitro and in vivo.
• To assess IR-817's potential for accurate tumor diagnosis, real-time monitoring, and safe anti-cancer therapy.

Main Methods:

• Synthesis of the novel theranostic agent IR-817.
• In vitro studies involving melanoma cell lines to assess IR-817 uptake and anti-cancer effects.
• In vivo experiments using zebrafish and mice xenograft models to evaluate tumor suppression.
• Mechanistic studies including cell cycle analysis and apoptosis assays.
• Immunohistochemical and hematoxylin and eosin staining for tissue analysis.

Main Results:

• IR-817 demonstrated preferential accumulation in melanoma cells via organic anion transporting polypeptide transporters.
• IR-817 selectively inhibited tumor cell growth by inducing mitochondrial-dependent intrinsic apoptosis and G0/G1 cell cycle arrest.
• IR-817 significantly suppressed xenograft tumor growth in zebrafish and mice.
• Histological analysis confirmed IR-817-induced apoptosis and inhibited proliferation without significant side effects.

Conclusions:

• The novel mitochondrial-targeting theranostic agent IR-817 exhibits potent anti-cancer effects against malignant melanoma.
• IR-817 holds promise for accurate tumor diagnosis, real-time monitoring, and safe therapeutic interventions.
• Further development of IR-817 could lead to improved clinical outcomes for melanoma patients.